Tymm, C. C., Vattakalam, R. M., Flum, D. R., Wright, J. D., & Fischkoff, K. N. (2024). Patient and Surgeon Attitudes Toward Opportunistic Salpingectomy During Nongynecological Surgeries for the Prevention of Ovarian Cancer: A Qualitative Study. Journal of Surgical Oncology. Portico. https://doi.org/10.1002/jso.28050

Brady, P. C. (2024). Ovarian tissue transplantation: a science coming of age. Fertility and Sterility, 121(2), 262–263. https://doi.org/10.1016/j.fertnstert.2023.12.001

Liu, J., O’Malley, D., Nieuwenhuysen, E. V., Moore, K., Hamilton, E., Yeku, O., Bouberhan, S., Hou, J., Schröder, D., Wang, B., Yoo, S.-Y., Govindraj, S., Brouwer-Visser, J., Peterman, M., Schmidt, T., Barnes, B., Lowy, I., Uldrick, T., Miller, E., & O’Cearbhaill, R. (2023). PO011LBA/#1512  Ubamatamab (MUC16XCD3 bispecific antibody) with or without cemiplimab (Anti-PD-1 antibody) in recurrent ovarian cancer: phase 1 clinical and biomarker results. Plenary 03: Oral Abstract Presentations – Ovarian Cancer. https://doi.org/10.1136/ijgc-2023-igcs.11

O’Cearbhaill, R. E., Moore, K. N., Yeku, O., Liu, J. F., Bouberhan, S., Hamilton, E. P., Hou, J. Y., Van Nieuwenhuysen, E., Papadimitriou, K., Yoo, S.-Y., Govindraj, S., Brouwer-Visser, J., Peterman, M., Schmidt, T., Barnes, B., Madia, P., Zhu, M., Uldrick, T. S., Miller, E. A., & O’Malley, D. (2023). 754P Ubamatamab (MUC16xCD3 bispecific antibody) with cemiplimab (anti-PD-1 antibody) in recurrent ovarian cancer: Phase I dose-escalation study. Annals of Oncology, 34, S516–S517. https://doi.org/10.1016/j.annonc.2023.09.1933

Praiss, A., Moukarzel, L., Zhu, Y., Derakhshan, F., Hoang, T., Pesci, G., Green, H., Hanlon, E., Gardner, G., Roche, K. L., Abu-Rustum, N., Sonoda, Y., Zivanovic, O., Chi, D., Weigelt, B., & Zamarin, D. (2023). Evolution of intra-tumoral and peripheral pro-tumorigenic response during primary cytoreductive surgery for ovarian cancer (187). Gynecologic Oncology, 176, S75–S76. https://doi.org/10.1016/j.ygyno.2023.06.573

Hou, J. Y., Chapman, J. S., Kalashnikova, E., Pierson, W., Smith-McCune, K., Pineda, G., Vattakalam, R. M., Ross, A., Mills, M., Suarez, C. J., Davis, T., Edwards, R., Boisen, M., Sawyer, S., Wu, H.-T., Dashner, S., Aushev, V. N., George, G. V., Malhotra, M., … Ford, J. M. (2022). Circulating tumor DNA monitoring for early recurrence detection in epithelial ovarian cancer. Gynecologic Oncology, 167(2), 334–341. https://doi.org/10.1016/j.ygyno.2022.09.004

Jorgensen, K., Wu, C.-F., Meernik, C., Nitecki, R., Melamed, A., & Rauh-Hain, J. A. (2022). 2022-RA-838-ESGO All-cause and cancer-specific mortality after fertility-sparing surgery for stage I epithelial ovarian cancer. Fertility/Pregnancy, A175.2-A176. https://doi.org/10.1136/ijgc-2022-esgo.375

Pereira-Eshraghi, C. F., Tao, R., Chiuzan, C. C., Zhang, Y., Shen, W., Lerner, J. P., Oberfield, S. E., & Sopher, A. B. (2022). Ovarian follicle count by magnetic resonance imaging is greater in adolescents and young adults with polycystic ovary syndrome than in controls. F&S Reports, 3(2), 102–109. https://doi.org/10.1016/j.xfre.2022.01.008